Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Italy
University of Campania Luigi Vanvitelli, Naples United Kingdom
Moorfields Eye Hospital, London Retina Clinic London, London